- Conditions
- Inflammatory Bowel Diseases, Liver Fibroses, Methotrexate
- Interventions
- Ultrasound Elastography
- Diagnostic Test
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 2 Years to 22 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 600
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Liver Fibrosis
- Interventions
- Not listed
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Fatty Liver, Cirrhosis
- Interventions
- 13C-Methacetin, Breath ID Machine
- Drug · Device
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Cirrhosis, Ascites, Hepatorenal Syndrome, Acute Kidney Injury
- Interventions
- OCE-205, Placebo
- Drug
- Lead sponsor
- Ocelot Bio, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 18 more
- Conditions
- Liver Disease
- Interventions
- 200 µg selenium as selenate, 400 µg selenium as selenate, 200 µg selenium as selenomethionine, Placebo
- Dietary Supplement
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Cirrhosis, Liver, End Stage Liver DIsease, Acute Kidney Injury, Liver Transplant; Complications
- Interventions
- Angiotensin II, Norepinephrine
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 114 participants
- Timeline
- 1995 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Liver Failure, Liver Diseases, Alcoholic, Liver Diseases, Pain, Postoperative, Transplant; Failure, Liver, Liver Cirrhosis, Biliary
- Interventions
- BRIDGE device
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Hepatobiliary Diseases
- Interventions
- Not listed
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 430 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2022
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Cirrhosis, Hepatocellular Carcinoma
- Interventions
- Erlotinib, Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • Boston, Massachusetts • Rochester, Minnesota + 2 more
- Conditions
- Hepatic Encephalopathy, Cirrhosis, Liver
- Interventions
- Rifamycin SV MMX, Placebo
- Drug · Other
- Lead sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
- Federal
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Chronic Hepatitis C Infection
- Interventions
- Fuzheng Huayu, Placebo
- Drug
- Lead sponsor
- Tarek Hassanein
- Individual
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 8
- States / cities
- Coronado, California • Palo Alto, California • Pasadena, California + 5 more
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease
- Interventions
- Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)
- Diagnostic Test
- Lead sponsor
- PharmaNest, Inc
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 1,519 participants
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Decompensated Cirrhosis
- Interventions
- Emricasan (25 mg), Emricasan (5 mg), Placebo
- Drug
- Lead sponsor
- Conatus Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 76
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 59 more
- Conditions
- Liver Cirrhosis, Hepatic Cell Carcinoma, Portal Hypertension
- Interventions
- Injection of a gadolinium contrast agen, Radiotracer Injection, Imaging
- Drug · Diagnostic Test
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity
- Interventions
- Metabolic surgery, Incretin-Based Therapy
- Procedure · Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Indianapolis, Indiana • Rochester, Minnesota + 1 more
- Conditions
- Liver Diseases, Fibrosis, Liver, Cirrhosis, Liver
- Interventions
- Intervention Group, Control Group
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Episode of Overt Hepatic Encephalopathy, Hepatic Encephalopathy
- Interventions
- ornithine phenylacetate, placebo intravenous infusion
- Drug
- Lead sponsor
- Ocera Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Coronado, California + 29 more
- Conditions
- Liver Cirrhosis
- Interventions
- Elastography
- Diagnostic Test
- Lead sponsor
- Midwest Biomedical Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Acute-On-Chronic Liver Failure, Ascites
- Interventions
- VS-01 on top of SOC, SOC (Control Group)
- Drug · Other
- Lead sponsor
- Genfit
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 13
- States / cities
- Sacramento, California • Washington D.C., District of Columbia • Tampa, Florida + 9 more
- Conditions
- Healthy Participants
- Interventions
- AZD2389, Itraconazole
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Cirrhosis, Liver
- Interventions
- Epigallocatechin gallate (EGCG), Placebo
- Drug · Other
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Cirrhosis
- Interventions
- Rotem
- Other
- Lead sponsor
- Scott Allen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Biliary Atresia, Alagille Syndrome, Alpha1 Anti-Trypsin Deficiency, Portal Hypertension, Liver Fibrosis, Cholestasis
- Interventions
- Liver Stiffness Measurement (LSM)
- Other
- Lead sponsor
- Arbor Research Collaborative for Health
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 552 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more